Peretinoin - Kowa

Drug Profile

Peretinoin - Kowa

Alternative Names: K-333; NIK-333

Latest Information Update: 03 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kowa Pharmaceutical
  • Class Antineoplastics; Diterpenes; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Apoptosis stimulants; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatocellular carcinoma

Most Recent Events

  • 14 Jul 2015 Marketing rights of Peretinoin licensed to Chugai Pharmaceutical in Japan
  • 08 May 2015 Phase-III development is still ongoing for Hepatocellular carcinoma in Japan
  • 16 Oct 2012 Phase-I clinical trials in Hepatocellular carcinoma (prevention of recurrence) in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top